Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics

Cytek BioSciences, Inc. (CTKB): $10.96

0.23 (+2.14%)

POWR Rating

Component Grades













CTKB Stock Price Chart Interactive Chart >

Price chart for CTKB

CTKB Price/Volume Stats

Current price $10.96 52-week high $28.70
Prev. close $10.73 52-week low $7.38
Day low $10.58 Volume 634,600
Day high $11.19 Avg. volume 962,228
50-day MA $9.82 Dividend yield N/A
200-day MA $15.36 Market Cap 1.47B

Cytek BioSciences, Inc. (CTKB) Company Bio

Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.

CTKB Latest News Stream

Event/Time News Detail
Loading, please wait...

CTKB Latest Social Stream

Loading social stream, please wait...

View Full CTKB Social Stream

Latest CTKB News From Around the Web

Below are the latest news stories about Cytek Biosciences Inc that investors may wish to consider to help them evaluate CTKB as an investment opportunity.

Cytek Biosciences Non-GAAP EPS of $0.09 misses by $0.02, revenue of $127.95M beats by $2.53M

Cytek Biosciences press release (CTKB): FY Non-GAAP EPS of $0.09 misses by $0.02.Revenue of $127.95M (+37.8% Y/Y) beats by $2.53M.

Seeking Alpha | February 23, 2022

Cytek Biosciences, Inc.''s (CTKB) CEO Wenbin Jiang on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results

2021 Revenue Increased 38% Compared to Prior Year

GlobeNewswire | February 23, 2022

Boeing And 3 Other Stocks Bought By Insiders

US stocks closed mixed on Wednesday following the release of minutes from the recent Federal Reserve meeting. Investors, meanwhile, focused on some notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Cytek Biosciences The Trade: Cytek Biosciences, Inc. (NASDAQ: CTKB ) Director Rajeev Shah acquired a total of 498,629 shares at an average price of...

Benzinga | February 17, 2022

Cytek to Participate in the 42nd Annual Cowen Health Care Conference

FREMONT, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating virtually in the upcoming 42 nd Annual Cowen Health Care Conference.

GlobeNewswire | February 16, 2022

Read More 'CTKB' Stories Here

CTKB Price Returns

1-mo 1.01%
3-mo 4.28%
6-mo -30.28%
1-year N/A
3-year N/A
5-year N/A
YTD -32.84%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4249 seconds.